As with most drug pricing battles, patients yet again are caught in the crossfire.
PBMs began by providing a huge service to payers, but in recent years, they've begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?
Digital innovation in Japan, health-tech trends, and social media top the list.
CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter's Vraylar sees positive results for bipolar depression
Express Scripts to limit opioid coverage; Novo's diabetes drug lowers glucose levels in trial; startup aims to give doctors access to a patient's total costs
CVS has a pharmacy text program to remind patients to refill their prescriptions and alert them when their medications are ready.
Dr. Glen Stettin is the chief innovation officer of Express Scripts.
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast
When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.
Walgreens Boots partners with PBM; Clinton proposes mental health plan; BI and Qualcomm to develop connected inhaler
The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.